Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function

• Published in: Frontiers in cell and developmental biology Vol. 11; p. 1276333
• Main Authors: Fernandes, Lorenzo M, Tresemer, Jeffrey, Zhang, Jing, Rios, Jonathan J, Scallan, Joshua P, Dellinger, Michael T
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 25.09.2023
• Subjects: Cell and Developmental Biology; complex lymphatic anomaly; Gorham-Stout disease; KRAS; lymphangiogenesis; lymphatic malformation; trametinib; trametinib; lymphangiogenesis; KRAS; Gorham-Stout disease; complex lymphatic anomaly; lymphatic malformation
• ISSN: 2296-634X; 2296-634X
• DOI: 10.3389/fcell.2023.1276333

Complex lymphatic anomalies (CLAs) are sporadically occurring diseases caused by the maldevelopment of lymphatic vessels. We and others recently reported that somatic activating mutations in can cause CLAs. However, the mechanisms by which activating mutations cause CLAs are poorly understood. Here, we show that KRAS expression in lymphatic endothelial cells (LECs) during embryonic development impairs the formation of lymphovenous valves and causes the enlargement of lymphatic vessels. We demonstrate that KRAS expression in primary human LECs induces cell spindling, proliferation, and migration. It also increases AKT and ERK1/2 phosphorylation and decreases the expression of genes that regulate the maturation of lymphatic vessels. We show that MEK1/2 inhibition with the FDA-approved drug trametinib suppresses KRAS -induced morphological changes, proliferation, and migration. Trametinib also decreases ERK1/2 phosphorylation and increases the expression of genes that regulate the maturation of lymphatic vessels. We also show that trametinib and Cre-mediated expression of a dominant-negative form of MEK1 ( ) suppresses KRAS -induced lymphatic vessel hyperplasia in embryos. Last, we demonstrate that conditional knockout of wild-type in LECs does not affect the formation or function of lymphatic vessels. Together, our data indicate that KRAS/MAPK signaling must be tightly regulated during embryonic development for the proper development of lymphatic vessels and further support the testing of MEK1/2 inhibitors for treating CLAs.